You are here

Gilead wins reversal of US$2.54b hepatitis C drug patent verdict


A US federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record US$2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

The verdict had been the largest ever in a US

Market voices on:

Powered by GET.comGetCom